<SEC-DOCUMENT>0000921895-25-000085.txt : 20250107
<SEC-HEADER>0000921895-25-000085.hdr.sgml : 20250107
<ACCEPTANCE-DATETIME>20250107190406
ACCESSION NUMBER:		0000921895-25-000085
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250102
FILED AS OF DATE:		20250107
DATE AS OF CHANGE:		20250107

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Lazar David E.
		CENTRAL INDEX KEY:			0001932843
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		25516156

	MAIL ADDRESS:	
		STREET 1:		PH THE TOWERS, TOWER 200, 30B
		STREET 2:		WINSTON CHURCHILL, PAITILLA
		CITY:			PANAMA CITY
		STATE:			R1
		ZIP:			07196

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>form312227001laz_01072025.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2025-01-02</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001130166</issuerCik>
        <issuerName>Cyclacel Pharmaceuticals, Inc.</issuerName>
        <issuerTradingSymbol>CYCC</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001932843</rptOwnerCik>
            <rptOwnerName>Lazar David E.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>PH THE TOWERS, TOWER 200, 30B</rptOwnerStreet1>
            <rptOwnerStreet2>WINSTON CHURCHILL, PAITILLA</rptOwnerStreet2>
            <rptOwnerCity>PANAMA CITY</rptOwnerCity>
            <rptOwnerState>R1</rptOwnerState>
            <rptOwnerZipCode>07196</rptOwnerZipCode>
            <rptOwnerStateDescription>PANAMA</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Executive Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Series C Convertible Preferred Stock</value>
                <footnoteId id="F2"/>
                <footnoteId id="F3"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F5"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <value>2025-01-02</value>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F4"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>2650000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">No shares of Common Stock are beneficially owned.</footnote>
        <footnote id="F2">On January 2, 2025, David E. Lazar (the &quot;Reporting Person&quot;) and Cyclacel Pharmaceuticals, Inc. (the &quot;Company&quot;), entered into a securies purchase agreement pursuant to which the Reporting Person will acquire (i) an aggregate of 1,000,000 shares of the Company's Series C Convertible Preferred Stock (the &quot;Series C Preferred Stock&quot;) at a price of $1.00 per share and (ii) an aggregate of 2,100,000 shares of the Company's Series D Convertible Preferred Stock (the &quot;Series D Preferred Stock&quot;, and together with the Series C Preferred Stock, the &quot;Preferred Stock&quot;) at a price of $1.00 per share. Each share of Series C Preferred Stock is convertible into 2.65 shares of the Company's Common Stock at any time, subject to certain ownership limitations. The initial closing took place on January 6, 2025, whereby the Reporting Person acquired 200,000 shares of Series C Preferred Stock for a total purchase price of $1,000,000.</footnote>
        <footnote id="F3">The Reporting Person will acquire the shares of Series D Preferred Stock at a subsequent closing, subject to satisfaction of certain closing conditions, for a total purchase price of $2,100,000. Each share of Series D Preferred Stock will be convertible into 110 shares of the Company's Common Stock at any time, subject to certain ownership limitations.</footnote>
        <footnote id="F4">The Series C Preferred Stock is perpetual and therefore has no expiration date.</footnote>
        <footnote id="F5">The shares of Series C Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ David E. Lazar</signatureName>
        <signatureDate>2025-01-07</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
